Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, investigator-sponsored, Phase 2 study of ISIS-TTRRx in patients with transthyretin amyloid-related cardiomyopathy which includes patients with familial amyloid cardiomyopathy (FAC) and patients with wild-type transthyretin (wt-TTR) amyloidosis

Next Previous
X
Search
Trial Profile

An open-label, investigator-sponsored, Phase 2 study of ISIS-TTRRx in patients with transthyretin amyloid-related cardiomyopathy which includes patients with familial amyloid cardiomyopathy (FAC) and patients with wild-type transthyretin (wt-TTR) amyloidosis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inotersen (Primary)
  • Indications Amyloidosis; Cardiomyopathies
  • Focus Therapeutic Use

    • Most Recent Events

    • 26 May 2020 Results (N267), pooled analysis of 5 studies (NEURO-TTR, OLE, EAP, ATU, and IST) assessing outcomes of enhanced monitoring for thrombocytopenia in patients receiving inotersen presented at the 6th Congress of the European Academy of Neurology
    • 26 Mar 2018 According to the Ionis Pharmaceuticals media release, new data from this study will be presented at the 16th International Symposium on Amyloidosis (ISA) 2018.
    • 26 Mar 2018 Results presented in the Ionis Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top